Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients

被引:689
作者
Sugarbaker, DJ
Flores, RM
Jaklitsch, MT
Richards, WG
Strauss, GM
Carson, JM
DeCamp, MM
Swanson, SJ
Bueno, R
Lukanich, JM
Baldini, EH
Mentzer, SJ
机构
[1] Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Surg Serv, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[5] Univ Massachusetts, Worcester, MA 01605 USA
关键词
D O I
10.1016/S0022-5223(99)70469-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Our aim was to identify prognostic variables for long-term postoperative survival in trimodality management of malignant pleural mesothelioma. Methods: From 1980 to 1997, 183 patients underwent extrapleural pneumonectomy followed by adjuvant chemotherapy and radiotherapy. Results: Forty-three women and 140 men (age range 31-76 years) had a median follow-up of 13 months. The perioperative mortality rate was 3.8 % (7 deaths) and the morbidity, 50%. Survival in the 176 remaining patients was 38% at 2 years and 15% at 5 years (median 19 months). Univariate analysis identified 3 prognostic variables associated with improved survival: epithelial cell type (52% 2-year survival, 21% 5-year survival, 26-month median survival; P =.0001), negative resection margins (44% at 2 years, 25% at 5 years, median 23 months; P =.02), and extrapleural nodes without metastases (42% at 2 years, 17% at 5 years, median 21 months; P =.004). Using the Cox proportional hazards, the relative risk of death was calculated for nonepithelial cell type (OR 3.0, CI 2.0-4.5; P < .0001), positive resection margins (OR 1.7, CI 1.2-2.6; P =.0082), and metastatic extrapleural nodes (OR 2.0, CI 1.3-3.2;P =.0026). Thirty-one patients with 3 positive variables had the best survival (68% 2-year survival, 46% 5-year survival, median 51 months; P =.013). A previously published staging system using these variables stratified survival (P <.05). Conclusions: (1) Multimodality therapy including extrapleural pneumonectomy is feasible in selected patients with malignant pleural mesotheliomas, (2) pre-resectional evaluation of extrapleural nodes may select patients for radical therapy, (3) microscopic resection margins affect long-term survival, highlighting the need for further investigation of locoregional control, and (4) patients with epithelial, margin-negative, extrapleural node-negative resection had extended survival.
引用
收藏
页码:54 / 63
页数:10
相关论文
共 47 条
[1]  
AISNER J, 1995, CHEST, V108, P1122
[2]  
ANTMAN KH, 1981, SEMIN ONCOL, V8, P313
[3]  
ANTMAN KH, 1993, CANC PRINCIPLES PRAC, P1489
[4]  
Antman KH, 1989, CANCER PRINCIPLES PR, P1399
[5]  
ANTONIA SJ, 1995, SEMIN ONCOL, V22, P34
[6]  
Baldini EH, 1997, ANN THORAC SURG, V63, P334
[7]  
Belli L, 1995, SEMIN ONCOL, V22, P29
[8]  
BLOIS G, 1995, SEMIN ONCOL S14, V22, P32
[9]  
BUNN PA, 1995, SEMIN ONCOL S9, V22, P26
[10]   PLEUROPNEUMONECTOMY IN MANAGEMENT OF DIFFUSE MALIGNANT MESOTHELIOMA OF PLEURA - EXPERIENCE WITH 29 PATIENTS [J].
BUTCHART, EG ;
ASHCROFT, T ;
BARNSLEY, WC ;
HOLDEN, MP .
THORAX, 1976, 31 (01) :15-24